challenge your expert sessions Breast cancer: precancerous lesions Alberto Costa European School of Oncology, Milan and Fondazione Maugeri, Pavia, Italy CML: resistance to tyrosine kinase inhibitors Andreas Hochhaus III. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany GIST Heikki Joensuu Central Hopital, Department of Oncology, Hyks, Finland molecular imaging in oncology Daniel Sullivan National Cancer Institute, National Institutes of Health, Bethesda, USA long term outcome after cancer treatment Sophie Fosså Rikshospitalet – Radiumhospitalet Trus, Department of Oncology, Oslo, Norway palliative care: evaluation instruments in daily clinical practice Florian Strasser Kantonsspital St. Gallen, Oncology/Hematology and Palliative Medicine, St. Gallen, Switzerland nasopharyngeal carcinoma Jean Pierre Armand Institut Gustave Roussy, Department of Medical Oncology, Villejuif, France hepatocellular carcinoma Julien Taieb Groupe Hospitalier Pitié Salpétrière, Paris, France drug resistance in solid tumors Patrick G. Johnston Drug Resistance Laboratory, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK MRI for breast cancer screening Martin Leach Institute of Cancer Research and the Royal Marsden Hospital, Cancer Research UK Clinical Magnetic Resonance Research Group, Sutton, United Kingdom by guest on February 5, 2016 http://annonc.oxfordjournals.org/ Downloaded from